Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 3:59 PM ET 5/17/2013
Last 10 Quotes:
What's This?
| Fiscal Q1 Ending 03/13 |
Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
|
Sales/Revenue |
145 | 1,967 | 110 | 108 | 114 |
Cost of Goods Sold (COGS) incl. D&A |
NA | 266 | NA | NA | NA |
COGS excluding D&A |
NA | 95 | NA | NA | NA |
Depreciation & Amortization Expense |
166 | 171 | 25 | 30 | 30 |
Gross Income |
NA | 1,701 | NA | NA | NA |
SG&A Expense |
2,921 | 4,406 | 5,419 | 7,347 | 7,015 |
Research & Development |
972 | 1,505 | 3,872 | 5,398 | 5,183 |
Other SG&A |
1,949 | 2,901 | 1,546 | 1,948 | 1,831 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
285 | 1,220 | 843 | -16 | 3,210 |
Non Operating Income/Expense |
1,000 | 0 | 0 | 0 | 0 |
Equity in Affiliates (Pretax) |
NA | NA | 0 | 0 | 0 |
Interest Expense |
64 | 64 | 67 | 92 | 124 |
Gross Interest Expense |
64 | 64 | 67 | 92 | 124 |
Pretax Income |
-2,291 | -3,988 | -6,244 | -7,345 | -10,265 |
Income Tax |
0 | 0 | -122 | 0 | 0 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
-2,291 | -3,988 | -6,122 | -7,345 | -10,265 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
-2,291 | -3,988 | -6,122 | -7,345 | -10,265 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | NA | 0 |
Net Income After Extraordinaries |
-2,291 | -3,988 | -6,122 | -7,345 | -10,265 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
-2,291 | -3,988 | -6,122 | -7,345 | -10,265 |
Operational EPS |
-0.09 | -0.13 | -0.24 | -0.36 | -0.41 |
EPS (basic) |
-0.09 | -0.16 | -0.27 | -0.36 | -0.54 |
EBITDA |
-2,777 | -2,535 | -5,310 | -7,239 | -6,902 |
Depreciation & Amortization Expense |
166 | 171 | 25 | 30 | 30 |
Common Shares Outstanding |
24,487 | 24,920 | 22,921 | 20,202 | 19,377 |
Basic Shares Outstanding |
24,487 | 24,920 | 22,921 | 20,202 | 19,377 |
Diluted Shares Outstanding |
24,487 | 24,920 | 22,921 | 20,202 | 19,377 |
Diluted EPS after Extraordinary Items |
-0.09 | -0.16 | -0.27 | -0.36 | -0.53 |
Discont. Operations Per Share |
NA | 0 | 0 | 0 | 0 |
Continued operations EPS |
NA | -0.16 | -0.27 | -0.36 | -0.51 |
*Figures in thousands of U.S. Dollars except shares outstanding.
